Efficacy and Safety of SR46349B (1 and 5mg/Day) Administered During 8 Weeks in Patients With Sleep Disorders in Fibromyalgia: Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study.
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2010
At a glance
- Drugs Eplivanserin (Primary)
- Indications Fibromyalgia; Sleep disorders
- Focus Therapeutic Use
- Sponsors Sanofi
- 09 Oct 2008 Official title updated from ClinicalTrials.gov record.
- 15 Nov 2007 Eplivanserin is expected to be launched in 2009.
- 19 Sep 2006 New trial record.